PT

Prem Tumkosit

Managing Director at Merck Global Health Innovation Fund (Merck & Co)

New York City Metropolitan Area

Overview 

Prem Tumkosit is a Health and Life Sciences Venture Capital Investor based in the New York City Metropolitan Area, with a background in financial modeling, strategy, and valuation. Notable career highlights include serving as Managing Director at Merck Global Health Innovation Fund and making investments in companies like Unnatural Products and Zapata Computing. Tumkosit holds an MBA from Yale School of Management and has worked at prestigious organizations such as Merck & Co, Accenture, and Credit Suisse, gaining experience in investment banking, management consulting, and strategic partnerships.

Work Experience 

Merck Global Health Innovation Fund (Merck & Co)

  • Managing Director

    2017 - Current

    Digital health and healthcare IT investor focused on opportunities in Oncology, Clinical Trials, and Real-World Evidence (geographic interests in N. America, Europe and Asia). Board responsibilities for: Antidote Technologies (UK), Ayogo Health (CA), Clinithink(UK), and Strata Oncology (US).

Accenture

  • Senior Manager, Accenture Strategy

    2012 - 2017

    Venture Capital, Private Equity and M&A Advisory (advised minority equity investments, M&A, due diligence, valuation and post-investment strategy).

CS

Credit Suisse

  • Investment Banking Associate

    2010 - 2012

    - Built and applied valuation models including product & business segment models for DCF valuation, leveraged buyout analysis, precedent acquisitions and comparable public company analysis - Account coverage responsibilities for large cap pharma, biotech & spec pharma, generic pharma, health care services and managed care companies

Credit Suisse Group is a financial services company that advises clients in all aspects of finance.

credit-suisse.com
A

Accenture

  • Consultant, Management Consulting - Strategy

    2005 - 2009

    Worked in the Health and Life Sciences Strategy Practice where I focused primarily on corporate strategy (including Licensing, Business Development and Mergers & Acquisition) in the Pharmaceuticals industry and operational performance in the Health Payer industry.

Accenture Ventures is a venture capital firm arm of Accenture, delivers innovative solutions with strategic partnerships and investments.

accenture.com

Accenture Development Partnerships

  • Consultant, Management Consulting - Strategy

    2009 - 2009

    Rotation through Accenture's highly selective international development organization to advise the operating model and global partnership strategy for a global health not for profit.

Uo

University of Pennsylvania School of Medicine

  • Student Researcher

    2001 - 2005

    Researched the molecular mechanisms of nicotine addiction through pharmacology studies. Publication: b3 Subunits Promote Expression and Nicotine-Induced Up-Regulation of Human Nicotinic a6* Acetylcholine Receptors Expressed in Transfected Cell Lines

Education 

Investments 

Unnatural Products

Series A

Total funding: $38M

Pragma Bio

Series A

Total funding: $15M

Absci

Corporate Round

Total funding amount not yet available

Zapata Computing

Series B

Total funding: $67M

Articles About Prem

Relevant Websites